Literature DB >> 23866714

Group B streptococcal colonization in 160 mother-baby pairs: a prospective cohort study.

Alberto Berardi1, Cecilia Rossi, Roberta Creti, Mariachiara China, Giovanni Gherardi, Claudia Venturelli, Fabio Rumpianesi, Fabrizio Ferrari.   

Abstract

OBJECTIVES: To identify the source of postnatal colonization with group B Streptococcus (GBS) and to evaluate the impact of intrapartum antibiotic prophylaxis (IAP) administration in newborn infant transmission. STUDY
DESIGN: A prospective, longitudinal study evaluated GBS colonization in 160 mother-baby pairs. Specimens were collected from the time of delivery to 8 weeks post-partum, from rectum, vagina, and milk of mothers, and from throat and rectum of neonates. Women were grouped according to their GBS status at discharge from the hospital: culture-positive carriers (n = 83), culture-negative carriers (n = 26), and noncarriers (n = 51). Newborns were considered colonized if GBS was yielded from at least 1 site.
RESULTS: A total of 35 (21.9%) neonates were colonized; 30 were born to culture-positive carriers, 2 to culture-negative carriers, and 3 to noncarriers. Infants of culture-positive carriers exposed to IAP were less likely to be colonized (15/57 vs 15/26, P = .01), or heavily colonized, (7/57 vs 9/26, P = .04). Of all newborns, those exposed to IAP and discharged GBS-free from hospital, often became colonized subsequently (12/57 vs 1/26, P = .09). Molecular typing analysis (available for 30 of 32 carrier mothers and their infants) confirmed an identical strain of GBS in all mother-baby pairs. Six of 83 culture-positive carrier mothers had a positive milk culture. Their respective neonates all were heavily colonized.
CONCLUSIONS: Newborns exposed to IAP and GBS-free at hospital discharge subsequently acquire GBS from their mothers. Culture-positive milk is associated with heavy neonatal colonization.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Keywords:  EOD; Early-onset disease; GBS; Group B Streptococcus; IAP; Intrapartum antibiotic prophylaxis; LOD; Late-onset disease; PFGE; Pulsed field gel electrophoresis; THB; Todd-Hewitt broth

Mesh:

Year:  2013        PMID: 23866714     DOI: 10.1016/j.jpeds.2013.05.064

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  16 in total

1.  Enhanced Postnatal Acquisition of Hypervirulent Group B Streptococcus.

Authors:  Adam J Ratner
Journal:  Clin Infect Dis       Date:  2019-10-30       Impact factor: 9.079

Review 2.  Drugs for the Prevention and Treatment of Sepsis in the Newborn.

Authors:  Sagori Mukhopadhyay; Kelly C Wade; Karen M Puopolo
Journal:  Clin Perinatol       Date:  2019-03-30       Impact factor: 3.430

3.  Prevalence of Group B Streptococcus Recto-Vaginal Colonization, Vertical Transmission, and Antibiotic Susceptibility Among Pregnant Women in Ethiopia: A Systematic Review and Meta-Analysis.

Authors:  Habtamu Bekele; Adera Debella; Tamirat Getachew; Bikila Balis; Dawit Tamiru; Addis Eyeberu; Getahun Tiruye; Mohammed Abdurke Kure; Sisay Habte; Bajrond Eshetu; Lemma Demissie Regassa; Sinetibeb Mesfin; Adisu Alemu; Yadeta Dessie; Kasiye Shiferaw
Journal:  Front Public Health       Date:  2022-05-16

4.  Probiotic interventions to reduce antepartum Group B streptococcus colonization: A systematic review and meta-analysis.

Authors:  Lisa Hanson; Leona VandeVusse; Emily Malloy; Mauricio Garnier-Villarreal; Lauren Watson; Alissa Fial; Marie Forgie; Katrina Nardini; Nasia Safdar
Journal:  Midwifery       Date:  2021-11-25       Impact factor: 2.640

5.  Group B Streptococcus among Pregnant Women and Newborns in Mirzapur, Bangladesh: Colonization, Vertical Transmission, and Serotype Distribution.

Authors:  Samir K Saha; Zabed B Ahmed; Joyanta K Modak; Hakka Naziat; Shampa Saha; Mohammad A Uddin; Maksuda Islam; Abdullah H Baqui; Gary L Darmstadt; Stephanie J Schrag
Journal:  J Clin Microbiol       Date:  2017-05-17       Impact factor: 5.948

6.  Maternal group B Streptococcus and the infant gut microbiota.

Authors:  A E Cassidy-Bushrow; A Sitarik; A M Levin; S V Lynch; S Havstad; D R Ownby; C C Johnson; G Wegienka
Journal:  J Dev Orig Health Dis       Date:  2015-08-12       Impact factor: 2.401

7.  Persistence of group B Streptococcus vaginal colonization and prevalence of hypervirulent CC-17 clone correlate with the country of birth: a prospective 3-month follow-up cohort study.

Authors:  Céline Plainvert; Olivia Anselem; Caroline Joubrel; Valérie Marcou; Amiel Falloukh; Amandine Frigo; Fatma Magdoud El Alaoui; Pierre-Yves Ancel; Pierre Henri Jarreau; Laurent Mandelbrot; François Goffinet; Claire Poyart; Asmaa Tazi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-08-18       Impact factor: 3.267

8.  Invasive Group B Streptococcus Disease With Recurrence and in Multiples: Towards a Better Understanding of GBS Late-Onset Sepsis.

Authors:  Mirjam Freudenhammer; Konstantinos Karampatsas; Kirsty Le Doare; Fabian Lander; Jakob Armann; Daniel Acero Moreno; Margaret Boyle; Horst Buxmann; Ruth Campbell; Victoria Chalker; Robert Cunney; Lorraine Doherty; Eleri Davies; Androulla Efstratiou; Roland Elling; Matthias Endmann; Jochen Essers; Roland Hentschel; Christine E Jones; Steffen Kallsen; Georgia Kapatai; Marcus Krüger; Shamez Ladhani; Theresa Lamagni; Diane Lindsay; Mary Meehan; Catherine P O'Sullivan; Darshana Patel; Arlene J Reynolds; Claudia Roll; Sven Schulzke; Andrew Smith; Anja Stein; Axel von der Wense; Egbert Voss; Christian Wieg; Christoph Härtel; Paul T Heath; Philipp Henneke
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

9.  Risk factors for Group B Streptococcus colonisation and disease in Gambian women and their infants.

Authors:  K Le Doare; S Jarju; S Darboe; F Warburton; A Gorringe; P T Heath; B Kampmann
Journal:  J Infect       Date:  2016-01-04       Impact factor: 6.072

Review 10.  Breast milk and Group B streptococcal infection: vector of transmission or vehicle for protection?

Authors:  Kirsty Le Doare; Beate Kampmann
Journal:  Vaccine       Date:  2014-04-13       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.